Search

Displaying results 1351 - 1360 of 4234 in total
  1. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)

  2. Drug

    Fluocinolone acetonide

    go.drugbank.com/drugs/DB00591
    ApprovedInvestigationalVet approved

    Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity. It has been used extensively in dermatological preparations and it has also been inv...

  3. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    [L49111] In the fall of 2024, an updated formulation covering the Omicron JN.1 subvariant was approved for use in Canada and the US.[L51394,L51399]

  4. Drug

    Ferric pyrophosphate citrate

    go.drugbank.com/drugs/DB13995
    Approved

    Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma. … [A31979] FPC is categorized in Japan as a second class OTC drug.

  5. Drug

    Monobenzone

    go.drugbank.com/drugs/DB00600
    ApprovedWithdrawn

    Monobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water.

  6. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    As of 24 July 2018, however, the U.S. … Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women

  7. Drug

    Agmatine

    go.drugbank.com/drugs/DB08838
    Experimental

    As an experimental drug, agmatine is being studied for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma … As an investigational drug, it is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy between the

  8. Drug

    Calcitriol

    go.drugbank.com/drugs/DB00136
    ApprovedInvestigationalNutraceutical

    Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin … Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing

  9. Drug

    Ramucirumab

    go.drugbank.com/drugs/DB05578
    ApprovedInvestigational

    Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing

  10. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is … [F4474] When provided as Biphentin®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through